The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
If Dr. Cooley has increased his holdings significantly to over 10% now, it suggests that he may be working with others to gain a larger stake in the company. These others could be holding shares just below the declaration threshold (3%) to avoid immediate attention.
✅ Motivation: There could be a few reasons for this type of move:
✅ Takeover Bid: The group might be planning a takeover bid to gain control of the company.
✅ Strategic Partnership: They could be seeking a partnership or large influence on the company's direction.
✅ Belief in Future Growth: They may genuinely believe in the company's future potential and intend to secure a large shareholding.
Summary of the key points from the CAP-XX Limited trading update:
✅ Strong Current Trading: Bookings and billings are significantly ahead of last year, indicating continued demand for CAP-XX's existing products.
✅ Progress on New Products: Trial shipments of pre-sample new products have begun. Development costs have largely been incurred for new DMH and SMD product lines.
✅ Improved Financial Position: Recent fundraising has strengthened the balance sheet, allowing for investment in sales/distribution expansion and supporting the launch of new products.
✅ Reduced Legal Costs: Significant outstanding legal costs related to the Maxwell/Tesla litigation have been mostly resolved.
✅ Cost Savings: Implemented cost-cutting measures have achieved US$0.5 million+ in annualised savings.
✅ Positive Outlook: The overall report suggests a positive trajectory with healthy demand, new product development on track, and an improved financial position.
✅ Sales Expansion: Investment in sales and distribution should fuel further growth for existing product lines.
✅ New Product Promise: DMH and SMD product launches, planned for 2025 and 2026 respectively, could significantly boost revenue.
Investor Confidence: The company's improved cost management and clearer path to profitability should build investor confidence.
Capital Markets Seminar: The upcoming seminar will provide investors with an in-depth look into the company's products, market strategy, and future direction.
CAP-XX Limited
("CAP-XX" or the "Company")
Trading update
CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, provides the following update.
Following the successful completion of the recent fundraise, the Board is pleased to announce that current trading on existing products remains strong, in line with management forecasts, and trial shipments of pre-samples of new product have recently commenced. Bookings and billings are 14% and 56% ahead respectively for the year to date compared to the comparative period in 2023, along with a current book to bill ratio of 1.12. The order backlog remains strong at close to US$1 million.
As previously stated, the proceeds from the fundraise are being used to improve the Company's financial position and provide working capital for investment. Key areas for investment include the continued expansion of the sales representative and distribution network, and working capital for the market introduction of the new DMH and SMD products. The vast bulk of the development costs of the latter has already been incurred, although some final commissioning of the DMH production line remains. An initial pre-series batch of fully functional DMH product is currently under lab evaluation and SMD testing remains on track. In addition, the Company expects to announce further patents during the next three months.
The Board considers that, apart from the final settlement of legal costs associated with the Maxwell/Tesla litigation, which it does not consider material, the only remaining payments for legal costs will be normal ongoing corporate legal expenses, including, for example, those associated with applications for patents.
In addition, the Company has implemented a comprehensive cost reduction program, which has delivered annualised operating cost savings in excess of US$0.5 million, and is expected to ensure that CAP-XX successfully overcomes its recent challenging phase.
The target for breakeven remains in the 2026 calendar year, assuming billings maintain their current growth trend. This is being supported by the recent investment in CAP-XX's international direct sales and marketing, the expansion of the distributor network, together with design wins and billings from our new product families, DMH and SMD, which will contribute in 2025 and 2026 respectively.
Following the conclusion of the financial year ending 30 June 2024, CAP-XX intends to provide a comprehensive update to investors on products and markets and corporate strategy at a Capital Markets seminar, which will be hosted on-line, details of which will be issued in due course.
Lars Stegmann, Chief Executive of CAP-XX, said "I'd like to thank our shareholders for their continued support. We look forward to the next exciting phase for the Company, as we prepare for our new product launches, supported by a strengthening sales and distribut
A couple of months ago, Dr. Cooley bought more at 1.50p and he's been adding more and more now.
Directors Deals for Cap-xx (CPX)
Announced Traded Action Notifier Price Currency Amount Holding
05-Dec-23 05-Dec-23 Buy Patrick Elliot 1.90 GBX 1,391,123 14,364,421
05-Dec-23 05-Dec-23 Buy Steen Feldskov 1.90 GBX 1,391,123 1,816,123
18-Nov-22 16-Nov-22 Buy Steen Feldskov 3.16 GBX 315,787 425,000
12-Jul-22 12-Jul-22 Buy Steen Feldskov 5.54 GBX 109,213 109,213
12-Jul-22 12-Jul-22 Buy Steen Feldskov 5.54 GBX 109,213 109,213
12-Jul-22 12-Jul-22 Buy Bruce Ferguson Grey 5.54 GBX 476,565 7,382,295
12-Jul-22 12-Jul-22 Buy Patrick Elliot 5.54 GBX 476,565 9,127,144
✅ Cooley-Led Consortium: If Dr. Cooley has increased his holdings significantly, it suggests that he may be working with others to gain a larger stake in the company. These others could be holding shares just below the declaration threshold (3%) to avoid immediate attention.
✅ Motivation: There could be a few reasons for this type of move:
✅ Takeover Bid: The group might be planning a takeover bid to gain control of the company.
✅ Strategic Partnership: They could be seeking a partnership or large influence on the company's direction.
✅ Belief in Future Growth: They may genuinely believe in the company's future potential and intend to secure a large shareholding.
I have taken a large chunk under 2.20p, can not believe pi was paid 10p couple of months ago (Jan 2024), and currently the discount rate is good for buying. It is a no-brainer to add some more for huge upside potential. Good luck all and do your own research.
Adding another 100k under 2p looks incredibly bargain basement. Anyone selling at these levels will regret it once the sale is done. It's impossible to buy large chunks!
It's all about taking a position, and next week is going to be big, in my humble opinion.
2.30p paid for 640k
I can't buy anything. My £5k order still hasn't been executed yet.
Summary:
✅ R&Q secured lender approval for the sale of Accredited to Onex Corporation.
✅ Regulatory approvals are ongoing, with some already received.
✅ The sale is still expected to close in Q2 2024.
✅ -Up Agreement reached with lenders, outlining terms for debt restructuring, sale consent, and use of proceeds.
✅ Discussions with regulators are ongoing, with some approvals already granted.
✅ Expected net proceeds from the sale are now between $65 million and $110 million.
✅ Proceeds will be used to reduce debt while maintaining liquidity for ongoing operations.
✅ R&Q is still exploring options to maximize value from its legacy insurance business.
3.39p paid, it's going to move this week.
✅ New Board Members: R&Q Insurance Holdings Ltd has appointed Stephen Welch and Lawrence Hirsh as Non-Executive Directors of the company.
✅ Expertise: Both Welch and Hirsh bring significant experience in financial restructuring, corporate management, and operational improvements.
✅ Focus: Their appointments are aimed at helping R&Q reduce debt and streamline its operations.
✅ Strategic Context: These appointments come as R&Q continues working towards finalizing the sale of its Accredited business unit and seeks approval for these changes from its lenders.
Background on R&Q Insurance Holdings Ltd
R&Q is a specialty insurance group with a focus on legacy solutions and program management.
The company operates globally with a presence in the US, Europe, and Bermuda.
Why This Matters
The addition of Welch and Hirsh to the R&Q board signals the company's commitment to:
✅ Addressing financial challenges: Their expertise will be crucial in the debt reduction process.
✅ Streamlining operations: The focus on operational improvements hints at cost-cutting measures.
✅ Completing the Accredited sale: The appointments support the ongoing sale process, likely by adding credibility and financial expertise to negotiations.
Accredited business is performing well. It is expected to recognize gross written premium of $2.1 billion and fee income of $90 million in 2023, representing an increase of 17% and 12.5% respectively over the prior year.
✅ Key Points
✅ Shareholder Approval: Shareholders of R&Q Insurance Holdings Ltd have voted to approve the sale of its subsidiary, Accredited.
✅ Expected Timeline: The closing of the sale is anticipated in either late Q1 2024 or early Q2 2024, but this could change.
Future Updates: The company will provide further announcements as the process continues.
Why is this significant?
✅ The sale of Accredited would be a major move for R&Q Insurance Holdings Ltd. This announcement signals progress towards that goal.
40-50p upside!
For new and potential investors: Read this!
If anyone wants to make serious money, then just buy and hold for the upcoming JV news.
The company is working closely with the government and Mining Commission to advance the project and moving toward commercialization.
Helium discovery in Tanzania: Helium One Global discovered a 4.7% helium concentration in the Rukwa Rift Basin, marking a significant breakthrough. This concentration is nearly 9,000 times above background levels.
➡️ Economic potential:
This discovery could position Tanzania as a major helium supplier, joining the few countries currently dominating the market. Helium is crucial for various applications, including medical equipment, electronics, and space exploration.
➡️ Helium One Global holds prospecting licences totalling more than 2,965 Kilometres Square across three distinct project areas which are Rukwa, Balangida, and Eyasi located within rift basins in the north and south-west of Tanzania.
➡️ The Company’s flagship Rukwa Project is located within the Rukwa Rift Basin covering 1,900 kilometre square in the south-west.
➡️ Today, helium is pro- duced primarily in just four countries including in the United States of America (USA), Qatar, Algeria and Russia, whereby limited number of suppliers result into an increase in demand and its price worldwide.
➡️ According to the African Union report, the continent has 30 per cent of the world’s mineral reserves with 91 per cent of platinum and hence it is up to all countries to harness the resource for the continent’s socioeco nomic transformation.
➡️ Government support:
The Tanzanian government is committed to supporting exploration for critical minerals like helium, which aligns with their clean energy transition goals.
➡️ Investment opportunities:
The discovery opens investment opportunities for establishing processing facilities and manufacturing industries using helium in Tanzania.
Key points:
🟢 This discovery could significantly impact the global helium market.
🟢 Tanzania has the potential to become a major helium supplier.
🟢 Further exploration and development are needed to assess the full potential of the reserves.
🟢 The government and private sector are collaborating to exploit this resource responsibly.